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rendering the patient unsuitable for inclusion.
Study Design and Protocol
We designed a multicenter, prospective, randomized, open-labeled, controlled study (Table 1) . Subjects were randomly assigned to receive standard therapy plus carperitide (carperitide group) or standard therapy without carperitide (control group). Carperitide was administered continuously by intravenous infusion for 48-72 h, initially at 0.01 g·kg -1 · min -1 and increased to ≤0.05 g·kg -1 ·min -1 based on each patient's physical condition. There were no limitations on the standard therapies for heart failure in either group, except for the use of aldosterone blockers such as spironolactone and potassium canrenoate.
Clinical Evaluation
Echocardiography was performed to assess LVEF before and 4 days after treatment, 1 day after termination of carperitide infusion, and before discharge from hospital. ECG monitoring was continued throughout the treatment period. Blood sampling was performed before, 6 and 24 h, and 4 days after starting the treatments, 1 day after termination of carperitide infusion, and before discharge. After informed consent was given, blood was collected by direct venipuncture of an antecubital vein while the patient was supine. Blood samples were collected into tubes containing EDTA and centrifuged within 30 min of collection. Serum concentrations of brain natriuretic peptide (BNP; radioimmunoassay, Shionoria, Shionogi, Osaka, Japan), heart-type fatty-acid-binding protein (H-FABP; 2-step direct sandwich-ELISA quantitative measures; Market-M, Dainippon Pharmaceutical Co, Osaka, Japan), troponin T (ELISA, Elecsys, Roche Diagnostics, Basel, Switzerland; detection limit: 0.01 ng/ml), creatinine, and -2-microglobulin were measured to evaluate left ventricular (LV) wall stress, membrane damage or myofibril damage of cardiomyocyte as the initial process of ongoing myocardial damage, 14 and glomerular filtration function, respectively. Etiology and past history of heart failure, as well as concurrent diseases (diabetes mellitus, hypertension, hyperlipidemia, renal diseases, hepatic diseases, and respiratory diseases) were recorded. Medications and clinical outcome were investigated for an average of 500 days. The evaluation of outcome after discharge included all deaths and rehospitalization for progressive heart failure, or severe arrhythmia. Written informed consent was given by all participants, and the study was approved by the institutional review board/independent ethics committee of each participating institution.
Statistical Analysis
All numerical data are expressed as mean ± SD. An error probability of p<0.05 was regarded as significant. Timerelated comparison of hemodynamic and biochemical parameters was analyzed by 1-way analysis of variance (ANOVA). Improvement of clinical signs and comparison of medications were analyzed by Whitney-Mann U-test and chi-square test. Among the patients' characteristics and clinical parameters, selected variables used in the Cox proportional hazard model for multivariate analysis with stepwise method were used to predict heart failure outcome. 
Results

Patients' Backgrounds
Etiology of heart failure was prior MI in 12 cases in the carperitide group and in 8 in the control group; NYHA classification was IV in 5 of the carperitide group and 10 of the control group; and the degree of dyspnea was judged as mild in 14 of the carperitide group and in 5 of the control group. There was no significant difference between the carperitide and control groups in the pretreatment background ( Table 2) .
Treatment of Heart Failure
The initial dose of carperitide was 0.024±0.023 g·kg -1 · min -1 (median, 0.01), with a treatment duration 102.43± 86.87 h (median, 71.98). Table 3 lists additional drug treatments administered intravenously during the study period. Intravenous vasodilators (nitroglycerin, isosorbide dinitrate, and nicardipine) were used significantly (p=0.0165) more frequently in the control group than in the carperitide group. There was no significant difference between the 2 groups in the use of other drugs (diuretics, inotropic agents). Medications used following discharge from hospital and at the end of follow-up are shown in Fig 1, with no significant difference noted between the 2 groups.
Duration of Hospitalization and Follow-up
The duration of hospitalization was 54.8±44.9 days in the carperitide group and 35.9±21.4 days in the control group. The follow-up period was 507±226 days in the carperitide group and 517±230 days in the control group. There was no significant difference between the 2 groups for either of these time periods.
Effects of Carperitide Treatment on ADHF Inpatients
At 24 h after starting treatment, serum ANP and cGMP levels were elevated significantly higher in the carperitide group (904.4±1,029.5 pg/ml and 15.4±6.4 pmol/ml, respec- tively) than in the control group (185.7±101.0 pg/ml and 11.3±5.5 pmol/ml, respectively). During this period, the H-FABP/creatinine ratio in the carperitide group (5.33±2.24) was significantly lower than that in the control group (7.33±3.05; p=0.0219, respectively). However, there were no significant differences in the changes in the other biomarkers analyzed.
Effects of Carperitide on Long-Term Prognosis
Outcomes of the all patients were able to be evaluated throughout the study period; 3 of 26 carperitide group patients (1 cardiac death and 2 re-hospitalizations) and 8 of 23 control group patients (re-hospitalizations in all) had cardiac events during the follow-up period. Fig 2 shows the Kaplan-Meier curves of death or rehospitalization in the carperitide and control groups. There was a significant difference between the 2 groups (11.5% vs 34.8%; p=0.0359). Cox proportional hazard model for multivariate analysis with stepwise method was performed to select variables predicting outcome of ADHF. The first model, including medication and patients' characteristics (Table 2 ) and clinical parameters (Table 4) as covariates, was developed using a stepwise method for variable selection. Medication with carperitide infusion and systolic BP on admission were selected. Subsequently, serum levels of biomarkers (H-FABP, creatinine, H-FABP/creatinine and -2 microglobulin), and -blocker therapy at the end of the study period were examined using the same manner. In the final model, carperitide infusion, systolic BP on admission ≥140 mmHg, and -blocker therapy at the end of the study period were judged as independent predictors of freedom from cardiac events in the ADHF population (Table 5) .
Discussion
Effects of Carperitide in ADHF Patients
In a previous study, Munzel et al reported the clinical efficacy of a short infusion of low-dose carperitide (0.075 g· kg -1 ·min -1 ; 20 h) in patients with chronic heart failure, and they concluded that the main responses that contributed to the improvement of heart failure symptoms were reduction of both central filling pressure and the plasma aldosterone level, and increased cardiac output, diuresis, glomerular filtration rate, and plasma cGMP level. 6 Saito et al also reported the clinical efficacy of a short infusion of carperitide (0.1 g·kg -1 ·min -1 ) in the treatment of chronic heart failure and attributed the clinical improvements to the drug's vasodilating property. 5 Shono et al found that carperitide infusion has a direct antioxidant effect on the failing heart. 4 Kitashiro et al reported good efficacy of carperitide infused over an average of 7 days for the treatment of heart failure, 7 and Suwa et al investigated real-world registry data and found that improvement of heart failure symptoms occurred in 82% of patients without significant adverse effects, other than transient lowering of BP, during 3 days of intravenous carperitide administration (0.05-0.1 g·kg -1 ·min -1 ) . 8 In the present study, low-dose carperitide was infused as the initial treatment (average initial dose, 0.024 g·kg -1 · min -1 ) for 3-4 days (average, 102 h). Although the initial dose was lower than those used in previous investigations, almost equivalent clinical effects were obtained with no significant adverse events.
In accordance with the cardiovascular effects of carperitide, the H-FABP/creatinine ratio decreased only in the carperitide group, suggesting possible inhibition of myocyte cell membrane damage in acute heart failure.
Colucci et al 15 and the Committee for Vasodilatation in the Management of Acute CHF (VMAC) Investigators 16 reported that the mechanism and effects of synthesized BNP (nesiritide) in heart failure were similar to those of carperitide. Fifer et al found the same effect of another vasodilating natriuretic peptide, anaritide. 17 
Decrease in H-FABP/Creatinine Ratio
We have previously shown that the presence of ongoing myocardial damage can be detected by increased levels of cardiac troponin T, a myofibril damage marker, and H-FABP, a membrane damage marker, in patients with chronic heart failure, which identifies increased risk for future cardiac events. 14 There is a difference in the release kinetics of troponin T and H-FABP following myocardial damage. Serum levels of H-FABP, a low-molecular-weight protein abundantly contained in the cytosol of cardiomyocytes and a useful marker of early-phase acute MI, are increased in patients with CHF, 14 and H-FABP measurement compensates for the limitations of troponin T in the early phase of acute MI. Thus it is reasonable to infer that analyzing the combination of markers might be clinically useful for pathophysiological assessment of ongoing myocardial damage in patients with CHF. We assessed the H-FABP/creatinine ratio rather than the H-FABP concentration per se because of renal clearance of H-FABP. In the present study, changes in the troponin T level were not significantly different between the carperitide and control groups. However, the H-FABP/creatinine ratio displayed significant decreases in the carperitide group compared with the control group, suggesting possible protection from cardiomyocyte membrane damage and resultant decreased H-FABP release. Although troponin T is an established sensitive marker of myocardial damage, elevated levels are relatively small, even in severe CHF, because most troponin T exists as a contractile apparatus in cardiac myocytes. In contrast, H-FABP concentrations elevate more readily when accompanying ongoing myocardial damage in CHF, as we previously reported. 14 Thus, measurement of H-FABP will detect ongoing myocardial damage and reflect the severity of CHF more definitely. In the present study, we measured serum H-FABP and troponin T levels simultaneously as part of our investigation into the possibility of cardioprotection by carperitide infusion therapy in the acute stage of heart failure. Thus the difference between the release kinetics of troponin T and H-FABP suggested the cardioprotective effect of carperitide Table 4 .
infusion therapy could be detected by H-FABP, which should be a more sensitive marker and have faster release kinetics than troponin T.
Improvement of Long-Term Prognosis in ADHF Patients
Chang et al 18 and Lenz et al 19 reported that nesiritide infusion shortened the period of hospitalization for the treatment of heart failure. Abraham et al also reported improvements in the outcome of heart failure patients receiving nesiritide that were similar to those observed in patients receiving intravenously infused nitroglycerin and superior to those seen with milrinone and dobutamine. 20 Additionally, Hammermeister et al 12 and Hayashi et al 13 reported that infused ANP suppressed remodeling of the left ventricle in patients with acute MI, resulting in prognostic improvement. Experimental studies have revealed that LV remodeling is closely related to activation of the angiotensin II and endothelin-1 systems. [21] [22] [23] Thus, infused ANP may improve the outcome of heart failure by inhibiting RAAS and endothelin-1 activation. Sezai et al 24 reported that carperitide infusion during emergency coronary artery bypass grafting could lower the incidence of postoperative cardiac events, as well as the peak levels of creatine kinase-MB and BNP. 24 On the other hand, there are no reports of the effects of ANP infusion on improvement of the long-term prognosis in ADHF. Therefore, we consider the results of this study to have new and important significance for the treatment of acute heart failure.
Cox regression analysis revealed that patients with systolic BP ≥140 mmHg before treatment and those starting -blocking agents during the follow-up period had better outcomes after discharge from hospital. We had assumed that drug treatment including diuretics and carperitide would be more problematic in heart failure patients with low BP than in patients with normal or high BP, as few reports have addressed systolic BP before treatment. [25] [26] [27] [28] 
Study Limitations
First, the number of cases was not large. Second, vasodilating drugs were more frequently used in the control group than in the carperitide group, probably because of the openlabel study design. Third, we could not clarify the cardiorenal protective effects of carperitide and the mechanism of improvement of heart failure in the present study, based on our analysis of cardiac markers, except for possible inhibition of myocyte membrane damage. In future research, a controlled large-scale double blind study would be useful to resolve the issues raised by our study.
Conclusions
Acute-phase low-dose carperitide infusion did improve the long-term prognosis of patients with ADHF.
